DLL4 is altered in 0.03% of breast carcinoma patients [3].

DLL4 is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain DLL4 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

DLL4 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains DLL4 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

DLL4 is an inclusion criterion in 1 clinical trial for colon carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DLL4 status and colon carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

DLL4 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains DLL4 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

DLL4 is altered in 0.0% of malignant solid tumor patients [3].

DLL4 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains DLL4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

DLL4 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains DLL4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].